JPMorgan lowered the firm’s price target on Sarepta to $202 from $205 and keeps an Overweight rating on the shares. The firm updated models in smid-cap biotechnology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT: